REXULTI
LIVE

Serial Number

79229625

Owner

Otsuka Pharmaceutical Co., Ltd.

Attorney

Kazuyo Morita

Filing Date

Dec 14, 2017

Add to watchlist:

No watchlists yet
View on USPTO

REXULTI Trademark

Serial Number: 79229625 • Registration: 5688217

REXULTI is a trademark filed by Otsuka Pharmaceutical Co., Ltd. on December 14, 2017. The trademark is classified under Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Otsuka Pharmaceutical Co., Ltd. (566 trademarks)

Chiyoda-ku, Tokyo , JP

Entity Type: 03

Trademark Details

Filing Date

December 14, 2017

Registration Date

March 5, 2019

Published for Opposition

December 18, 2018

Cancellation Date

September 19, 2025

Goods & Services

Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; Injection devices for medical purposes; syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing, and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; Medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
May 19, 2026 INTR
NEW REPRESENTATIVE AT IB RECEIVED
Feb 19, 2026 NREP
CANCELLED SECTION 71
Sep 19, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 5, 2024 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 12, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 26, 2019 FICS
FINAL DISPOSITION PROCESSED
Jun 26, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 5, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 5, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 18, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 18, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Dec 15, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 28, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 28, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 28, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 8, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 23, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2018 CRFA
ASSIGNED TO LIE
Oct 17, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 8, 2018 TROA
REFUSAL PROCESSED BY IB
May 12, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 23, 2018 RFCS
REFUSAL PROCESSED BY MPU
Apr 23, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 18, 2018 RFCR
NON-FINAL ACTION WRITTEN
Apr 17, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Apr 14, 2018 MAFR
ASSIGNED TO EXAMINER
Apr 10, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 10, 2018 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 9, 2018 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 5, 2018 REPR